Press Releases March 31, 2026 08:00 PM

Apollo to Announce First Quarter 2026 Financial Results on May 6, 2026

Apollo Global Management to Release Q1 2026 Financial Results on May 6

By Maya Rios
Share
Twitter Reddit Facebook LinkedIn
APO

Apollo Global Management announced it will release its financial results for the first quarter of 2026 on May 6, 2026, prior to the market opening. Management will host a webcast to review the results and provide insights into the company's ongoing operations and financial position. Apollo is a leading global alternative asset manager with a diverse portfolio including asset management and retirement services through Athene, managing assets worth approximately $938 billion as of the end of 2025.

Apollo to Announce First Quarter 2026 Financial Results on May 6, 2026
APO
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Apollo plans to announce Q1 2026 financial results on May 6, 2026.
  • Management will hold a live webcast to review results and discuss company performance.
  • Apollo manages approximately $938 billion in assets, with operations spanning alternative asset management and retirement services.
  • The company services a broad client base with investment solutions across credit, private equity, and retirement products.

NEW YORK, April 01, 2026 (GLOBE NEWSWIRE) -- Apollo (NYSE: APO) plans to release financial results for the first quarter 2026 on Wednesday, May 6, 2026, before the opening of trading on the New York Stock Exchange. Management will review Apollo’s financial results at 8:30 am ET via public webcast available on Apollo’s Investor Relations website at ir.apollo.com. A replay will be available one hour after the event.

Apollo distributes its earnings releases via its website and email lists. Those interested in receiving firm updates by email can sign up for them here.

About Apollo

Apollo is a high-growth, global alternative asset manager. In our asset management business, we seek to provide our clients excess return at every point along the risk-reward spectrum from investment grade credit to private equity. For more than three decades, our investing expertise across our fully integrated platform has served the financial return needs of our clients and provided businesses with innovative capital solutions for growth. Through Athene, our retirement services business, we specialize in helping clients achieve financial security by providing a suite of retirement savings products and acting as a solutions provider to institutions. Our patient, creative, and knowledgeable approach to investing aligns our clients, businesses we invest in, our employees, and the communities we impact, to expand opportunity and achieve positive outcomes. As of December 31, 2025, Apollo had approximately $938 billion of assets under management. To learn more, please visit www.apollo.com.

Contacts

Noah Gunn
Global Head of Investor Relations
Apollo Global Management, Inc.
(212) 822-0540
[email protected]

Joanna Rose
Global Head of Corporate Communications
Apollo Global Management, Inc.
(212) 822-0491
[email protected]


Risks

  • Financial performance in Q1 2026 may be affected by volatile market conditions affecting alternative asset values.
  • Challenges in the broader economic environment could impact asset growth and client investment returns.
  • Potential regulatory changes affecting alternative asset management and retirement services could influence business operations.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026